

David S Goldfarb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6804935/publications.pdf>

Version: 2024-02-01

235
papers

10,027
citations

34016

52
h-index

43802

91
g-index

270
all docs

270
docs citations

270
times ranked

9034
citing authors

#	ARTICLE	IF	CITATIONS
1	Plant-Based Milk Alternatives and Risk Factors for Kidney Stones and Chronic Kidney Disease. , 2022, 32, 363-365.		12
2	Nutritional prevention and treatment of urinary tract stones. , 2022, , 685-697.		0
3	Cystinuria: an update on pathophysiology, genetics, and clinical management. Pediatric Nephrology, 2022, 37, 1705-1711.	0.9	17
4	Editorial: New perspectives on estimated glomerular filtration rate and health equity. Current Opinion in Nephrology and Hypertension, 2022, 31, 157-159.	1.0	0
5	Comparison of Selective vs Empiric Pharmacologic Preventive Therapy of Kidney Stone Recurrence With High-Risk Features. Urology, 2022, 164, 74-79.	0.5	5
6	Extracorporeal Treatment for Methotrexate Poisoning. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 602-622.	2.2	8
7	Update on Uric Acid and the Kidney. Current Rheumatology Reports, 2022, 24, 132-138.	2.1	13
8	Comparison of Empiric Preventative Pharmacologic Therapies on Stone Recurrence Among Patients with Kidney Stone Disease. Urology, 2022, 166, 111-117.	0.5	2
9	Assessing the effect of extracorporeal treatments for lithium poisoning. British Journal of Clinical Pharmacology, 2021, 87, 214-215.	1.1	2
10	Urine and stone analysis for the investigation of the renal stone former: a consensus conference. Urolithiasis, 2021, 49, 1-16.	1.2	43
11	Comparison of Selective Versus Empiric Pharmacologic Preventative Therapy With Kidney Stone Recurrence. Urology, 2021, 149, 81-88.	0.5	12
12	Bariatric surgery in a patient with cystinuria. Clinical Nephrology Case Studies, 2021, 9, 54-58.	0.3	0
13	Urinary stone disease prevalence and associations in cystic fibrosis. Urolithiasis, 2021, 49, 415-423.	1.2	6
14	A Report of Two Cases: Unlearning Lactic Acidosis. Clinical Practice and Cases in Emergency Medicine, 2021, 2, 182-185.	0.1	2
15	Extracorporeal treatments for isoniazid poisoning: Systematic review and recommendations from the EXTRIP workgroup. Pharmacotherapy, 2021, 41, 463-478.	1.2	4
16	Dietary Inflammatory Index and Cardiovascular Disease Risk Factors in Patients With Chronic Kidney Disease and Type 2 Diabetes. Current Developments in Nutrition, 2021, 5, 412.	0.1	0
17	Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup. Critical Care, 2021, 25, 201.	2.5	14
18	Feasibility and Acceptability of mHealth Interventions for Managing Hyperphosphatemia in Patients Undergoing Hemodialysis. , 2021, 31, 403-410.		10

#	ARTICLE	IF	CITATIONS
19	Challenging patient phenotypes in the management of anaemia of chronic kidney disease. <i>International Journal of Clinical Practice</i> , 2021, 75, e14681.	0.8	5
20	Effect of antibiotic treatment on <i>Oxalobacter formigenes</i> colonization of the gut microbiome and urinary oxalate excretion. <i>Scientific Reports</i> , 2021, 11, 16428.	1.6	9
21	Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease. <i>Kidney International Reports</i> , 2021, 6, 2862-2884.	0.4	15
22	Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning. <i>Kidney International</i> , 2021, 100, 720-736.	2.6	6
23	Editorial: Controversies in nephrologic covidology. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 173-175.	1.0	1
24	Sodium bicarbonate therapy for acute respiratory acidosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 223-230.	1.0	11
25	Prevalence of low molecular weight proteinuria and Dent disease 1 <i>CLCN5</i> mutations in proteinuric cohorts. <i>Pediatric Nephrology</i> , 2020, 35, 633-640.	0.9	14
26	Sex differences in the temperature dependence of kidney stone presentations: a population-based aggregated case-crossover study. <i>Urolithiasis</i> , 2020, 48, 37-46.	1.2	35
27	Assessment of health-related quality of life in patients with cystinuria on tiopronin therapy. <i>Urolithiasis</i> , 2020, 48, 313-320.	1.2	12
28	Managing Hyperkalemia: Another Benefit of Exercise in People With Chronic Kidney Disease?. , 2020, 30, 380-383.		8
29	Editorial. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 199-200.	1.0	1
30	Nephrolithiasis in women. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 201-206.	1.0	10
31	Occupational kidney stones. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 232-236.	1.0	10
32	Are conventional stone analysis techniques reliable for the identification of 2,8-dihydroxyadenine kidney stones? A case series. <i>Urolithiasis</i> , 2020, 48, 337-344.	1.2	1
33	The Association of Mesalamine With Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 72-76.	0.6	13
34	Vitamin D and Kidney Stones. <i>Urology</i> , 2020, 139, 1-7.	0.5	6
35	Evaluation and Medical Management of Patients with Cystine Nephrolithiasis: A Consensus Statement. <i>Journal of Endourology</i> , 2020, 34, 1103-1110.	1.1	25
36	Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 880-882.	2.2	101

#	ARTICLE	IF	CITATIONS
37	Effects of ambient temperature and humidity on kidney stone admissions in Brazil. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2020, 42, 133-135.	0.4	2
38	Acute Peritoneal Dialysis During the COVID-19 Pandemic at Bellevue Hospital in New York City. <i>Kidney360</i> , 2020, 1, 1345-1352.	0.9	11
39	Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. <i>Rheumatology</i> , 2019, 58, 61-69.	0.9	17
40	Managing proteinâ€energy wasting in hemodialysis patients: A comparison of animalâ€and plantâ€based protein foods. <i>Seminars in Dialysis</i> , 2019, 32, 41-46.	0.7	12
41	Water to prevent kidney stones: tap vs bottled; soft vs hard â€ does it matter?. <i>BJU International</i> , 2019, 124, 905-906.	1.3	8
42	Access to Care for VA Dialysis Patients During Superstorm Sandy. <i>Journal of Primary Care and Community Health</i> , 2019, 10, 215013271986359.	1.0	5
43	Recurrent Calcium Kidney Stones. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1388-1390.	2.2	3
44	A Twin Study of Genetic Influences on Nephrolithiasis in Women and Men. <i>Kidney International Reports</i> , 2019, 4, 535-540.	0.4	39
45	Effect of thiazolidinedione therapy on the risk of uric acid stones. <i>Kidney International</i> , 2019, 95, 1022-1024.	2.6	4
46	Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria. <i>Urolithiasis</i> , 2019, 47, 549-555.	1.2	13
47	Blood volume analysis as a guide for dry weight determination in chronic hemodialysis patients: a crossover study. <i>BMC Nephrology</i> , 2019, 20, 47.	0.8	4
48	Editorial. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 128-129.	1.0	0
49	The use of antibiotics and risk of kidney stones. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 311-315.	1.0	17
50	Differences in national and international guidelines regarding use of kidney stone formers as living kidney donors. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 140-147.	1.0	7
51	Cystinuria: genetic aspects, mouse models, and a new approach to therapy. <i>Urolithiasis</i> , 2019, 47, 57-66.	1.2	57
52	Urine proteomic profiling in patients with nephrolithiasis and cystinuria. <i>International Urology and Nephrology</i> , 2019, 51, 593-599.	0.6	9
53	Empiric therapy for kidney stones. <i>Urolithiasis</i> , 2019, 47, 107-113.	1.2	30
54	Nephrolithiasis in the Elderly. , 2019, , 201-212.		0

#	ARTICLE	IF	CITATIONS
55	Assessment of the combination of temperature and relative humidity on kidney stone presentations. <i>Environmental Research</i> , 2018, 162, 97-105.	3.7	39
56	Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with Adenine phosphoribosyltransferase deficiency (APRTd): A clinical trial. <i>European Journal of Internal Medicine</i> , 2018, 48, 75-79.	1.0	26
57	The Healthy Hearts and Kidneys (HHK) study: Design of a 2 Å– 2 RCT of technology-supported self-monitoring and social cognitive theory-based counseling to engage overweight people with diabetes and chronic kidney disease in multiple lifestyle changes. <i>Contemporary Clinical Trials</i> , 2018, 64, 265-273.	0.8	21
58	Personalized Intervention in Monogenic Stone Formers. <i>Journal of Urology</i> , 2018, 199, 623-632.	0.2	17
59	Assessment and misassessment of potassium, phosphorus, and protein in the hemodialysis diet. <i>Seminars in Dialysis</i> , 2018, 31, 479-486.	0.7	14
60	Oral Antibiotic Exposure and Kidney Stone Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1731-1740.	3.0	109
61	Falsely elevated salicylate concentration in a patient with hypertriglyceridemia. <i>Toxicology Communications</i> , 2018, 2, 1-2.	0.3	2
62	Tamm-Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, F1062-F1076.	1.3	28
63	Early Recognition and Management of Rare Kidney Stone Disorders. <i>Urologic Nursing</i> , 2018, 37, 81.	0.1	16
64	Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2017, 30, 251-261.	0.7	31
65	Opioid Overuse or NSAID Underuse? ÅÅResponse to the Pain Guide. <i>American Journal of Kidney Diseases</i> , 2017, 69, 865.	2.1	4
66	Refining Diagnostic Approaches in Nephrolithiasis: Incomplete Distal Renal Tubular Acidosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1380-1382.	2.2	6
67	Does Vitamin D Supplementation Cause Kidney Stones?. <i>Journal of Urology</i> , 2017, 197, 280-281.	0.2	2
68	The Role of the 24-Hour Urine Collection in the Prevention of ÅKidney Stone Recurrence. <i>Journal of Urology</i> , 2017, 197, 1084-1089.	0.2	57
69	Phosphate Additive Avoidance in Chronic Kidney Disease. <i>Diabetes Spectrum</i> , 2017, 30, 101-106.	0.4	6
70	Case Study - Case Studies in Cystinuria. <i>Urologic Nursing</i> , 2017, 37, 90-3.	0.1	0
71	Early Recognition and Management of Rare Kidney Stone Disorders. <i>Urologic Nursing</i> , 2017, 37, 81-9, 102.	0.1	7
72	Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. <i>Journal of Nephrology</i> , 2016, 29, 715-734.	0.9	122

#	ARTICLE	IF	CITATIONS
73	<sc></sc>-Cystine Diamides as <sc></sc>-Cystine Crystallization Inhibitors for Cystinuria. Journal of Medicinal Chemistry, 2016, 59, 7293-7298.	2.9	21
74	The role of the microbiome in kidney stone formation. International Journal of Surgery, 2016, 36, 607-612.	1.1	76
75	Enteric hyperoxaluria: an important cause of end-stage kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 375-382.	0.4	87
76	Nutrient Non-equivalence: Does Restricting High-Potassium Plant Foods Help to Prevent Hyperkalemia in Hemodialysis Patients?. , 2016, 26, 282-287.		137
77	A RANKL Wrinkle: Denosumab-Induced Hypocalcemia. Journal of Medical Toxicology, 2016, 12, 305-308.	0.8	34
78	Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1305-1312.	2.2	106
79	Potassium citrate decreases urine calcium excretion in patients with hypocitraturic calcium oxalate nephrolithiasis. Urolithiasis, 2016, 44, 145-148.	1.2	30
80	The exposome for kidney stones. Urolithiasis, 2016, 44, 3-7.	1.2	22
81	The Presence of <i>Oxalobacter formigenes</i> in the Microbiome of Healthy Young Adults. Journal of Urology, 2016, 195, 499-506.	0.2	51
82	MP34-16 PATIENTS WITH CYSTINURIA HAVE ALKALINE URINE DUE TO RENAL LOSS OF SULFATE PRECURSORS. Journal of Urology, 2015, 193, .	0.2	0
83	The Clinical Impact of Accurate Cystine Calculi Characterization Using Dual-Energy Computed Tomography. Case Reports in Radiology, 2015, 2015, 1-5.	0.5	2
84	Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Annals of Emergency Medicine, 2015, 66, 165-181.	0.3	98
85	Institutional Characteristics Associated with Receipt of Emergency Care for Obstructive Pyelonephritis at Community Hospitals. Journal of Urology, 2015, 193, 851-856.	0.2	4
86	Extracorporeal Treatment for Lithium Poisoning. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 875-887.	2.2	128
87	The New Epidemiology of Nephrolithiasis. Advances in Chronic Kidney Disease, 2015, 22, 273-278.	0.6	87
88	Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. Nature Communications, 2015, 6, 7486.	5.8	317
89	Helicobacter pylori, Oxalobacter formigenes, and risk of kidney stones. Medical Hypotheses, 2015, 84, 601.	0.8	3
90	Cystine Growth Inhibition Through Molecular Mimicry: a New Paradigm for the Prevention of Crystal Diseases. Current Rheumatology Reports, 2015, 17, 33.	2.1	20

#	ARTICLE	IF	CITATIONS
91	Hypothesis: Urbanization and exposure to urban heat islands contribute to increasing prevalence of kidney stones. <i>Medical Hypotheses</i> , 2015, 85, 953-957.	0.8	18
92	Dysphoria Induced in Dialysis Providers by Secondary Hyperparathyroidism. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 9-11.	2.2	1
93	Urine proteomic analysis in cystinuric children with renal stones. <i>Journal of Pediatric Urology</i> , 2015, 11, 217.e1-217.e6.	0.6	13
94	The Search for Monogenic Causes of Kidney Stones. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 507-510.	3.0	10
95	Radioisotope blood volume measurement in hemodialysis patients. <i>Hemodialysis International</i> , 2014, 18, 406-414.	0.4	13
96	A Nomogram for the Prediction of Kidney Stone Recurrence. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2685-2687.	3.0	32
97	MP25-14 KIDNEY STONES ARE A RISK FACTOR FOR CKD AND ESRD. <i>Journal of Urology</i> , 2014, 191, .	0.2	1
98	Health-related quality of life (HRQoL) in cystine compared with non-cystine stone formers. <i>Urolithiasis</i> , 2014, 42, 53-60.	1.2	34
99	Guidelines for Reporting Case Studies on Extracorporeal Treatments in Poisonings: Methodology. <i>Seminars in Dialysis</i> , 2014, 27, 407-414.	0.7	68
100	Novel Cystine Ester Mimics for the Treatment of Cystinuria-induced Urolithiasis in a Knockout Mouse Model. <i>Urology</i> , 2014, 84, 1249.e9-1249.e15.	0.5	21
101	Risk of Chronic and End Stage Kidney Disease in Patients with Nephrolithiasis. <i>Journal of Urology</i> , 2014, 192, 1440-1445.	0.2	92
102	In Reply to "Role of Sodium Restriction in Recurrent Stone Formers With Hyperoxaluria". <i>American Journal of Kidney Diseases</i> , 2014, 64, 478-479.	2.1	1
103	Facilitating the transition from physiology to hospital wards through an interdisciplinary case study of septic shock. <i>BMC Medical Education</i> , 2014, 14, 78.	1.0	4
104	Urinary Lithogenic Risk Profile in Recurrent Stone Formers With Hyperoxaluria: A Randomized Controlled Trial Comparing DASH (Dietary Approaches to Stop Hypertension)-Style and Low-Oxalate Diets. <i>American Journal of Kidney Diseases</i> , 2014, 63, 456-463.	2.1	68
105	Zero Dark Thirty: A Nephrologist at the Movies. <i>American Journal of Kidney Diseases</i> , 2014, 63, A20-A22.	2.1	0
106	Treatment of calcium nephrolithiasis in the patient with hyperuricosuria. <i>Journal of Nephrology</i> , 2014, 27, 601-605.	0.9	13
107	Twice-Weekly and Incremental Hemodialysis Treatment for Initiation of Kidney Replacement Therapy. <i>American Journal of Kidney Diseases</i> , 2014, 64, 181-186.	2.1	144
108	Medical Management of Kidney Stones: AUA Guideline. <i>Journal of Urology</i> , 2014, 192, 316-324.	0.2	692

#	ARTICLE	IF	CITATIONS
109	Symptomatic Central Venous Stenosis in a Hemodialysis Patient Leading to Loss of Arteriovenous Access: A Case Report and Literature Review. <i>Nephron Extra</i> , 2014, 4, 50-54.	1.1	14
110	Cystine nephrolithiasis. <i>Translational Andrology and Urology</i> , 2014, 3, 228-233.	0.6	33
111	Cystinuria: Assessing and Managing Risk. , 2014, , 105-114.		0
112	Taxi cab syndrome: a review of the extensive genitourinary pathology experienced by taxi cab drivers and what we can do to help. <i>Reviews in Urology</i> , 2014, 16, 99-104.	0.9	12
113	Hereditary causes of kidney stones and chronic kidney disease. <i>Pediatric Nephrology</i> , 2013, 28, 1923-1942.	0.9	213
114	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 62, 849-859.	2.1	206
115	Metabolic Evaluation of First-time and Recurrent Stone Formers. <i>Urologic Clinics of North America</i> , 2013, 40, 13-20.	0.8	32
116	Pharmacologic Treatment of Kidney Stone Disease. <i>Urologic Clinics of North America</i> , 2013, 40, 21-30.	0.8	23
117	Dialysis Initiation: What's the Rush?. <i>Seminars in Dialysis</i> , 2013, 26, 650-657.	0.7	45
118	Kidney Stones and the Risk of Coronary Heart Disease. <i>American Journal of Kidney Diseases</i> , 2013, 62, 1039-1041.	2.1	5
119	Surgical Decompression is Associated with Decreased Mortality in Patients with Sepsis and Ureteral Calculi. <i>Journal of Urology</i> , 2013, 189, 946-951.	0.2	81
120	2107 PATHOPHYSIOLOGICAL BASES OF INTRA-RENAL CALCIFICATION IN MICE DEFICIENT FOR TAMM-HORSFALL PROTEIN (UIROMODULIN). <i>Journal of Urology</i> , 2013, 189, .	0.2	0
121	Optimum Nutrition for Kidney Stone Disease. <i>Advances in Chronic Kidney Disease</i> , 2013, 20, 165-174.	0.6	94
122	Monosodium Urate Stones Are Rare, and Urine pH Is Not Low in Cystinuria. <i>American Journal of Kidney Diseases</i> , 2013, 62, 179-180.	2.1	5
123	Health Status and Quality of Life in Patients With Stable Coronary Artery Disease and Chronic Kidney Disease Treated With Optimal Medical Therapy or Percutaneous Coronary Intervention (Post Hoc) Tj ETQq1 1 0.784374 rgBT1k Overlo		
124	Evidence for inheritance of medullary sponge kidney. <i>Kidney International</i> , 2013, 83, 193-196.	2.6	5
125	Minimal Change Disease and IgA Deposition: Separate Entities or Common Pathophysiology?. <i>Case Reports in Nephrology</i> , 2013, 2013, 1-3.	0.2	2
126	A Pilot Study of the Effect of Sodium Thiosulfate on Urinary Lithogenicity and Associated Metabolic Acid Load in Non-Stone Formers and Stone Formers with Hypercalciuria. <i>PLoS ONE</i> , 2013, 8, e60380.	1.1	12

#	ARTICLE	IF	CITATIONS
127	Cocktail Party Nephrology. JAMA - Journal of the American Medical Association, 2013, 309, 2561.	3.8	2
128	Medication adherence assessment in a clinical trial with centralized follow-up and direct-to-patient drug shipments. Clinical Trials, 2013, 10, 441-448.	0.7	9
129	Update on cystinuria. Current Opinion in Nephrology and Hypertension, 2013, 22, 427-431.	1.0	47
130	Bilateral Tubulocystic Renal Cell Carcinomas in Diabetic End-Stage Renal Disease: First Case Report with Cytogenetic and Ultrastructural Studies. Rare Tumors, 2013, 5, 185-188.	0.3	2
131	Stone Disease in Living-Related Renal Donors: Long-Term Outcomes for Transplant Donors and Recipients. Journal of Endourology, 2013, 27, 1520-1524.	1.1	21
132	Randomized Controlled Trial of Febuxostat Versus Allopurinol or Placebo in Individuals with Higher Urinary Uric Acid Excretion and Calcium Stones. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1960-1967.	2.2	56
133	Review: Thiazide, citrate, or allopurinol reduces recurrence after kidney stone episodes. Annals of Internal Medicine, 2013, 159, J12.	2.0	2
134	Impact of mild chronic hyponatremia on falls, fractures, osteoporosis, and death. American Journal of Orthopedics, 2013, 42, 522-7.	0.7	6
135	A Woman with Recurrent Calcium Phosphate Kidney Stones. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1172-1178.	2.2	39
136	A New CJASN Feature. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 2.	2.2	3
137	Effect of Vitamin D Repletion on Urinary Calcium Excretion among Kidney Stone Formers. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 829-834.	2.2	68
138	Extracorporeal Treatment for Thallium Poisoning. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1682-1690.	2.2	41
139	The EXTRIP (<i>EXtracorporeal TReatments In Poisoning</i>) workgroup: Guideline methodology. Clinical Toxicology, 2012, 50, 403-413.	0.8	103
140	The Older Adult Patient and Kidney Function. The Consultant Pharmacist, 2012, 27, 431-444.	0.4	14
141	Capital Punishment: What Is the Appropriate Abbreviation for Partial Pressure of a Gas?. American Journal of the Medical Sciences, 2012, 344, 255-256.	0.4	0
142	Laxative Abuse, Eating Disorders, and Kidney Stones: A Case Report and Review of the Literature. American Journal of Kidney Diseases, 2012, 60, 295-298.	2.1	18
143	842 ADMINISTRATION OF A UNIQUE RENOPROTECTIVE COCKTAIL IN A RAT MODEL: CAN WARM ISCHEMIA-REPERFUSION INJURY BE PREVENTED?. Journal of Urology, 2012, 187, .	0.2	0
144	2302 CYSTINE ANALOGS AS POTENTIAL THERAPEUTIC AGENTS FOR CYSTINURIA. Journal of Urology, 2012, 187, .	0.2	0

#	ARTICLE	IF	CITATIONS
145	1843 MANAGEMENT OF CYSTINURIC PATIENTS IN A DEDICATED STONE CLINIC DECREASES STONE EVENTS. Journal of Urology, 2012, 187, .	0.2	0
146	2256 CLINICAL VALIDATION OF A NOVEL ASSAY USED FOR MONITORING TREATMENT OF PATIENTS WITH CYSTINURIA. Journal of Urology, 2012, 187, .	0.2	0
147	Uric Acid Stones and Hyperuricosuria. Advances in Chronic Kidney Disease, 2012, 19, 413-418.	0.6	25
148	Effect of diet orange soda on urinary lithogenicity. Urological Research, 2012, 40, 237-241.	1.5	19
149	Genetic Causes of Kidney Stones and Kidney Failure. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 2-18.	1.3	7
150	Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors. Journal of Rheumatology, 2011, 38, 1385-1389.	1.0	37
151	The Hemodialysis Machine: Where the Nephrologists and Toxicologists Meet. Advances in Chronic Kidney Disease, 2011, 18, 157-159.	0.6	0
152	Have Advances in Extracorporeal Removal Techniques Changed the Indications for Their Use in Poisonings?. Advances in Chronic Kidney Disease, 2011, 18, 172-179.	0.6	16
153	Prevalence of Contraindications and Prescription of Pharmacologic Therapies for Gout. American Journal of Medicine, 2011, 124, 155-163.	0.6	168
154	Oral Antibiotic Treatment of Helicobacter pylori Leads to Persistently Reduced Intestinal Colonization Rates with Oxalobacter formigenes. Journal of Endourology, 2011, 25, 1781-1785.	1.1	55
155	Amelioration of Renal Ischemia-Reperfusion Injury With a Novel Protective Cocktail. Journal of Urology, 2011, 186, 2448-2454.	0.2	43
156	New and emerging therapies for gout. Clinical Investigation, 2011, 1, 1563-1575.	0.0	1
157	Melamine-related kidney stones and renal toxicity. Nature Reviews Nephrology, 2011, 7, 267-274.	4.1	97
158	Ambient temperature as a contributor to kidney stone formation: implications of global warming. Kidney International, 2011, 79, 1178-1185.	2.6	116
159	Potential Pharmacologic Treatments for Cystinuria and for Calcium Stones Associated with Hyperuricosuria: Figure 1.. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2093-2097.	2.2	24
160	Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients. Nephron Extra, 2011, 1, 212-216.	1.1	1
161	Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Advances in Therapy, 2010, 27, 634-647.	1.3	189
162	Update on the Pathophysiology and Management of Uric Acid Renal Stones. Current Rheumatology Reports, 2010, 12, 125-129.	2.1	44

#	ARTICLE	IF	CITATIONS
163	109: Febuxostat in Gout: Serum Urate Responses in Uric Acid Overproducers vs. Underexcretors. American Journal of Kidney Diseases, 2010, 55, B59.	2.1	1
164	The Normal Saline Ceremony. American Journal of Kidney Diseases, 2010, 56, A28-A29.	2.1	4
165	Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia. International Journal of Nephrology and Renovascular Disease, 2010, 3, 1.	0.8	9
166	A Pilot Clinical Study to Evaluate Changes in Urine Osmolality and Urine cAMP in Response to Acute and Chronic Water Loading in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 693-697.	2.2	66
167	Continuous Renal Replacement Therapy Does Not Have a Clear Role in the Treatment of Poisoning. Nephron Clinical Practice, 2010, 115, c1-c6.	2.3	30
168	Response to "Chemistry misconceptions associated with understanding calcium and phosphate homeostasis". American Journal of Physiology - Advances in Physiology Education, 2010, 34, 23-23.	0.8	1
169	Extracorporeal Removal Techniques for the Poisoned Patient: A Review for the Intensivist. Journal of Intensive Care Medicine, 2010, 25, 139-148.	1.3	49
170	Citrate, Malate and Alkali Content in Commonly Consumed Diet Sodas: Implications for Nephrolithiasis Treatment. Journal of Urology, 2010, 183, 2419-2423.	0.2	47
171	Pathophysiology and treatment of cystinuria. Nature Reviews Nephrology, 2010, 6, 424-434.	4.1	183
172	Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney International, 2010, 78, 1178-1185.	2.6	128
173	Crystal Growth Inhibitors for the Prevention of <sc> </sc> -Cystine Kidney Stones Through Molecular Design. Science, 2010, 330, 337-341.	6.0	212
174	Metabolic Investigations: When and in Whom. , 2010, , 659-665.		1
175	Gout and its comorbidities. Bulletin of the NYU Hospital for Joint Diseases, 2010, 68, 199-203.	0.7	42
176	Association of nephrolithiasis prevalence rates with ambient temperature in the United States: a re-analysis. Kidney International, 2009, 76, 798.	2.6	33
177	Asymptomatic Nephrolithiasis Detected by Ultrasound. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 680-684.	2.2	38
178	Optimal Medical Therapy With or Without Percutaneous Coronary Intervention for Patients With Stable Coronary Artery Disease and Chronic Kidney Disease. American Journal of Cardiology, 2009, 104, 1647-1653.	0.7	94
179	Effect of the MTHFR C677T and A1298C Polymorphisms on Survival in Patients With Advanced CKD and ESRD: A Prospective Study. American Journal of Kidney Diseases, 2009, 53, 779-789.	2.1	19
180	Treatment of Pregabalin Toxicity by Hemodialysis in a Patient With Kidney Failure. American Journal of Kidney Diseases, 2009, 54, 1127-1130.	2.1	51

#	ARTICLE	IF	CITATIONS
181	Homocysteine Lowering and Cognition in CKD: The Veterans Affairs Homocysteine Study. <i>American Journal of Kidney Diseases</i> , 2009, 54, 440-449.	2.1	64
182	Effect of two sports drinks on urinary lithogenicity. <i>Urological Research</i> , 2009, 37, 41-46.	1.5	30
183	Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. <i>Kidney International</i> , 2009, 75, 15-24.	2.6	124
184	Future Directions in Nephrolithiasis Research. <i>Advances in Chronic Kidney Disease</i> , 2009, 16, 3-4.	0.6	0
185	Prospects for Dietary Therapy of Recurrent Nephrolithiasis. <i>Advances in Chronic Kidney Disease</i> , 2009, 16, 21-29.	0.6	23
186	The underutilization of hemodialysis in patients with salicylate poisoning. <i>Kidney International</i> , 2009, 75, 1349-1353.	2.6	30
187	Nephrolithiasis. <i>Annals of Internal Medicine</i> , 2009, 151, ITC2.	2.0	13
188	Cystinuria. <i>Seminars in Nephrology</i> , 2008, 28, 181-191.	0.6	104
189	The Association of Nephrolithiasis With Hypertension and Obesity: A Review. <i>American Journal of Hypertension</i> , 2008, 21, 257-264.	1.0	164
190	Homocysteine Lowering and Severe Kidney Disease—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, .	3.8	0
191	Use of hemodialysis and hemoperfusion in poisoned patients. <i>Kidney International</i> , 2008, 74, 1327-1334.	2.6	110
192	Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. <i>Kidney International</i> , 2008, 74, 1588-1595.	2.6	19
193	Effect of Homocysteine Lowering on Mortality and Vascular Disease in Advanced Chronic Kidney Disease and End-stage Renal Disease. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1163.	3.8	405
194	A Randomized, Controlled Trial of Lactic Acid Bacteria for Idiopathic Hyperoxaluria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 745-749.	2.2	84
195	Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. <i>Journal of Applied Physiology</i> , 2007, 102, 1313-1322.	1.2	172
196	Adverse Metabolic Side Effects of Thiazides: Implications for Patients With Calcium Nephrolithiasis. <i>Journal of Urology</i> , 2007, 177, 1238-1243.	0.2	54
197	Diagnosis of Medullary Sponge Kidney by Computed Tomographic Urography. <i>American Journal of Kidney Diseases</i> , 2007, 50, 146-150.	2.1	32
198	Predictive Value of a Positive Fecal Occult Blood Test Increases as the Severity of CKD Worsens. <i>American Journal of Kidney Diseases</i> , 2006, 48, 580-586.	2.1	29

#	ARTICLE	IF	CITATIONS
199	Positive Predictive Value of Fecal Occult Blood Testing in Asymptomatic Average-Risk Patients with Varying Degrees of Chronic Kidney Disease. <i>Gastrointestinal Endoscopy</i> , 2006, 63, AB201.	0.5	0
200	The Role of Continuous Renal Replacement Therapy in the Treatment of Poisoning. <i>Seminars in Dialysis</i> , 2006, 19, 402-407.	0.7	67
201	Chitosan does not reduce post-prandial urinary oxalate excretion. <i>Urological Research</i> , 2006, 34, 227-230.	1.5	1
202	The Availability and Use of Charcoal Hemoperfusion in the Treatment of Poisoned Patients. <i>American Journal of Kidney Diseases</i> , 2006, 48, 239-241.	2.1	68
203	Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia. <i>Dialysis and Transplantation</i> , 2006, 35, 660-671.	0.2	6
204	Strategies for preventing calcium oxalate stones. <i>Cmaj</i> , 2006, 174, 1407-1409.	0.9	76
205	A twin study of genetic and dietary influences on nephrolithiasis: A report from the Vietnam Era Twin (VET) Registry. <i>Kidney International</i> , 2005, 67, 1053-1061.	2.6	226
206	Use of a probiotic to decrease enteric hyperoxaluria. <i>Kidney International</i> , 2005, 68, 1244-1249.	2.6	151
207	Nephrolithiasis complicating treatment of diabetes insipidus. <i>Urological Research</i> , 2005, 33, 244-246.	1.5	3
208	Effect of Cystine-Binding Thiol Drugs on Urinary Cystine Capacity in Patients with Cystinuria. <i>Journal of Endourology</i> , 2005, 19, 429-432.	1.1	49
209	Conversion of Chronic Hemodialysis Patients from Erythropoietin Alfa to Darbeoetin Alfa. <i>Hospital Pharmacy</i> , 2004, 39, 333-337.	0.4	2
210	Hyperkalemia after the Publication of RALES. <i>New England Journal of Medicine</i> , 2004, 351, 2448-2450.	13.9	12
211	Microorganisms and Calcium Oxalate Stone Disease. <i>Nephron Physiology</i> , 2004, 98, p48-p54.	1.5	26
212	Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study. <i>Clinical Trials</i> , 2004, 1, 451-460.	0.7	21
213	Uric acid stones following hepatic transplantation. <i>Urological Research</i> , 2004, 32, 423-426.	1.5	2
214	AA-type amyloidosis associated with non-Hodgkin's lymphoma: A case report. <i>Human Pathology</i> , 2004, 35, 1041-1044.	1.1	18
215	How life imitates baseball. <i>The Pharos of Alpha Omega Alpha-honor Medical Society Alpha Omega Alpha</i> , 2004, 67, 34-5.	0.1	0
216	Patients at the center: in our practice, and in our use of language. <i>ACP Journal Club</i> , 2004, 140, A14; author reply A14-5.	0.1	1

#	ARTICLE	IF	CITATIONS
217	Patients at the center: in our practice, and in our use of language. ACP Journal Club, 2004, 140, A14.	0.1	2
218	Ichthyotoxic ARF after fish gallbladder ingestion: a large case series from Vietnam. American Journal of Kidney Diseases, 2003, 41, 220-224.	2.1	38
219	The association of nephrolithiasis with cystic fibrosis. American Journal of Kidney Diseases, 2003, 42, 1-11.	2.1	88
220	Increasing prevalence of kidney stones in the United States. Kidney International, 2003, 63, 1951-1952.	2.6	69
221	Randomized Controlled Trial of Clopidogrel plus Aspirin to Prevent Hemodialysis Access Graft Thrombosis. Journal of the American Society of Nephrology: JASN, 2003, 14, 2313-2321.	3.0	221
222	The Absence of Rhabdomyolysis-induced Renal Failure Following the World Trade Center Collapse. American Journal of Medicine, 2002, 113, 260.	0.6	16
223	Reconsideration of the 1988 NIH Consensus Statement on Prevention and Treatment of Kidney Stones: Are the Recommendations Out of Date?. Reviews in Urology, 2002, 4, 53-60.	0.9	11
224	EFFECT OF GRAPEFRUIT JUICE ON URINARY LITHOGENICITY. Journal of Urology, 2001, 166, 263-267.	0.2	81
225	Diagnostic value of iron indices in hemodialysis patients receiving epoetin. Kidney International, 2001, 60, 300-308.	2.6	23
226	Indications for Hospitalization of Patients With Hyperkalemia. Archives of Internal Medicine, 2000, 160, 1605.	4.3	39
227	CLINICAL USE OF CYSTINE SUPERSATURATION MEASUREMENTS. Journal of Urology, 2000, 164, 1481-1485.	0.2	93
228	CLINICAL USE OF CYSTINE SUPERSATURATION MEASUREMENTS. Journal of Urology, 2000, , 1481-1485.	0.2	5
229	Beverages, diet, and prevention of kidney stones. American Journal of Kidney Diseases, 1999, 33, 398-400.	2.1	19
230	Fomepizole for ethyleneglycol poisoning. Lancet, The, 1999, 354, 1646.	6.3	3
231	Subcutaneous Compared with Intravenous Epoetin in Patients Receiving Hemodialysis. New England Journal of Medicine, 1998, 339, 578-583.	13.9	292
232	Calcified Mass in a Patient on Long-Term Hemodialysis. New England Journal of Medicine, 1998, 338, 1427-1427.	13.9	2
233	Renal Stone Disease in Older Adults. Clinics in Geriatric Medicine, 1998, 14, 367-382.	1.0	24
234	Immune complex glomerulonephritis in patients coinfectd with human immunodeficiency virus and hepatitis C virus. American Journal of Kidney Diseases, 1997, 29, 514-525.	2.1	85

#	ARTICLE	IF	CITATIONS
235	Metabolic Evaluation and Prevention of Renal Stone Disease. , 0, , 642-650.		0